119-54-0 | Sigma-Aldrich

Aldrich Polymer Products Application - Combi

Soc. 1997, 119, 4882. (b) Kaldor, S.W. et al. Tetrahedron Lett. 1996, 37, 7193. (c) Parlow, J.J. et al. J. Org. Chem. 1997, 62, 5908. (d) Flynn, D.L. et al. J. Am. Chem. Soc. 1997, 119, 4874.

MILLIPLEX®MAP Human Myokine Panel is an optimized quantitative immunoassay that simultaneously measures 15 novel muscle-secreted factors

00 0 7, 00 0 8, 00 0 9, 00 0 0 50 ,0 00 10 0, 00 0 15 0, 00 0 20 0, 00 0 25 0, 00 0 30 0, 00 010 10 0 1, 00 0 10 ,0 00 10 0, 00 0 10 10 0 1, 00 0 10 ,0 00

Spare parts for Mobius® FlexReady Solution with Smart Flexware® Assemblies For Chromatography and TFF

(pH/UV/Conductivity) LOCALE SECTION D-D 117 119 120 121 123 118 Includes TC gasket and set of o-rings for instrumentation 119 117 121 120 123 118 37 7.

Data Sheet - N5511 - Lot 064K8812

Spectrum m/z Abundance 41 42 55 65 78 84 104 119 133 162 40 50 60 70 80 90 100 110 120 130 140 150 160 170 0 5000

Data Sheet - n5511 - Lot 041K8803

80 90 100 110 120 130 140 150 160 170 0 20000 40000 60000 80000 00000 20000 m/z Abundance 42 51 55 65 67 78 84 92 102 105 119 130

Anti-CD93, Clone R3, Phycoerythrin Conjugated - Data Sheet

Ped. Research 54: 724 3. Danet G.H. et al. (2002). PNAS 99: 10441 USA & Canada

Data Sheet - 77237

et al., Arch. Biochem. Biophys., 298, 651-657 (1992). Rennie, C. et al., Clin. Chim. Acta, 98, 119-125 (1979). Natural Killer Cells Warren, H.S. and Skipsey, L.J., Immunol., 74, 78-85 (

Simple process strategies to increase the utilization of Protein A media in clinical manufacturing

Ultra Plus Single Flow 95 54 20% Eshmuno® A Dual Flow 95 53 18% 0% 5% 10% 15% pIgG mAb A mAb B mAb C Increase in DBC using dual flow rate

The Effective Use of Protein Kinase Inhibitors

14 26 90 101 82 61 48 75 38 99 86 8 6 54 66 10 83 105 106 103 99 98 103 104 101 67 95 77 101 95 82 99 67 96 90 76 93 63

The Effective Use of Protein Kinase Inhibitors

14 26 90 101 82 61 48 75 38 99 86 8 6 54 66 10 83 105 106 103 99 98 103 104 101 67 95 77 101 95 82 99 67 96 90 76 93 63

Examination of Non-Specifically Bound Proteins and Peptides Following Depletion of Twenty High Abundance Proteins from Human Plasma

9 593 12 470 10 562 11 IPI00021854 Apolipoprotein A-II precursor 128 2 140 2 165 2 164 3 133 2 119 2 96 1 96 1 124 1 166 2 IPI00022229 Apolipoprotein B-100 precursor 78 2 64

Nano Juice™ Transfection Kit

Web www.vwr.com Printed in the USA $37 $49 $63 $200 $876 $54 $97 $173 $36 $119 $239 $36 $119 $34 $59 $51 $50 $198

Resins for solution phase organic synthesis

RREEFFEERREENNCCEESS [1] R. J. Booth & J. C. Hodges (1997) J. Am. Chem. Soc., 119, 4882. [2] M. W. Creswell, et al. (1998) Tetrahedron, 54, 3983. [3] C. Blackburn, et al. (1998) Tetrahedron Lett., 39, 3635. [4

Anti-NeuN, clone A60 - Data Sheet

44 (0) 23 8026 2233 Australia +61 3 9839 2000 • Germany +49-6192-207300 • ISO Registered worldwide www.chemicon.com • custserv@chemicon.com • techserv@chemicon.com 12-28-2006/MAB377/CB 54) Baquet

Reprint: Protein A Intermediate Wash Strategies

Equilibration Bu�er Equilibration Bu�er 100 80 60 40 20 0 100 80 60 40 20 0 MAb 1 300 250 200 150 100 50 0 1,000 800 600 400 200 0 98 98 98 96 273 159 921 143 Figure

16-3 67-16-3 490-82-4 299-35-4 3419-28-1 89285-03-0 13100-57-7 532-43-4 154-87-0 89285-03-0 54-64-8 119-80-2 26921-17-5 30165-96-9 396-01-1 1006-23-1 19375

Protein A Intermediate Wash Strategies (Melissa Holstein, Kristen Cotoni and Nanying Bian) Bioprocess International February 2015

Equilibration Bu�er Equilibration Bu�er 100 80 60 40 20 0 100 80 60 40 20 0 MAb 1 300 250 200 150 100 50 0 1,000 800 600 400 200 0 98 98 98 96 273 159 921 143 Figure

Protein Tyrosine Phosphatases- Potential Roles in Disease

d e r : 1 . 8 0 0 . 3 2 5 . 3 0 1 0 ( U S ) T e c h n i c a l S

Biologics 28.1

Receptor that Suppresses Metastasis C ALBIOCHEM® introduces the 54-amino acid Metastin, as well as two derivative peptides. Metastin (45-54) is found to be about ten times more potent than the parent peptide

BRAND Katalog EN

13 5 0+ 54 96 -w el l, el ev at ed s ki rt 78 13 5 2 96 -w el l, fu ll sk irt 78 13 5 3 96 -w

Eshmuno®CPS resin

fa ct or ti te r ( m g/ m L) Elution volume (mL) elution pool 85 87 101 119 121 104 81 63 56 34 1419 column load feed elution pool† (mg/mL CV)

Percoll - Product Information Sheet

et al., Arch. Biochem. Biophys., 298, 651-657 (1992). Rennie, C. et al., Clin. Chim. Acta, 98, 119- 125 (1979). Natural Killer Cells Warren, H.S. and Skipsey, L.J., Immunol., 74, 78-85 (1991

Corticotropin-Releasing Factor Receptor Antagonists- Potential Novel Therapies for Human Disease

d e r : 1 . 8 0 0 . 3 2 5 . 3 0 1 0 ( U S ) T e c h n i c a l S

Product Information Sheet-04634772001

5 6 7 http://sigmaaldrich.com 14 sigma-aldrich.com 09 17 .0 46 97 54 50 01 6 6. Supplementary Information y Version: 06

Antibody Sourcebookﾙ Sixth Edition

5�9�05 500 µg €119 Protein G, Fluorescein Conjugate IC 5�9�26 1 mg €164 Protein G, Peroxidase Conjugate ELISA, IB 5�9�22 500 µg €119 Protein G, Recombinant, E. coli AB PUR 5�9�0� 1 mg 5 mg €82

An Update on Ligands for Prostanoid Receptors

J.Y., et al., Br. J. Pharmacol., 127, 204-210 (1999). 23. Seiler, S., et al., Prostaglandins, 40, 119-130 (1990). 24. Trist, D.G., et al., Br. J. Pharmacol., 96, 301-306 (1989). 25. Hamid-Bloomfield, S

Protocol- EZGRT-89K|EZGRT-89BK

Human Insulin 0% Human Leptin 0% Human GLP-1 0% Human C-peptide 0% Human Amylin 0% Glucagon 0% Rat/Mouse Ghrelin (Active) 52%* Des-Octanoyl Rat/Mouse Ghrelin 54%* *Purified ghrelin only. This kit

S&E Campaign Lab Tools - Tables for laboratory use

) Vanadium V 23 50.942 6.09 g/cm3 1910 3407 134 1.45 1.63 0, 2, 3, 4, 5 [Ar] 3d3 4s2 0.01 6.7462 -1.186 V (II), -1.876 V (III) Xenon Xe 54 131.29 4.49 g/L -111.74 -108.09 218 - 2.60

Building blocks for peptide synthesis

occasionally observed [51-54], and appears to be very sequence dependent. In these instances washing the support with 20% DIPEA in DMF/water (90:10) [51] or 5 mM sodium hydroxide in methanol [54] has been found

Product Information Sheet - CKH200A

Sample Type Average % Recovery Range Cell culture media 98 91 - 109% Serum 107 94 - 119% EDTA plasma 110 98 - 128% Heparin plasma 101 89 - 115% Citrate plasma